|Source||Humanized (from mouse)|
|Target||Clumping factor A|
|Chemical and physical data|
|Molar mass||147.590 kg/mol g·mol−1|
|(what is this?)|
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus.
It was developed by Inhibitex.
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
- Clinical trial number NCT00198289 at ClinicalTrials.gov
- Pan; Lorenzotti, S.; Zoncada, A. (2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
- John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|